Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy

Ashitha L. Vijayan, Vanimaya, Shilpa Ravindran, R. Saikant, S. Lakshmi, R. Kartik and Manoj. G

Abstract

Background: Sepsis is a global healthcare problem, characterized by whole body inflammation in response to microbial infection, which leads to organ dysfunction. It is becoming a frequent complication in hospitalized patients. Early and differential diagnosis of sepsis is needed critically to avoid unnecessary usage of antimicrobial agents and for proper antibiotic treatments through the screening of biomarkers that sustains with diagnostic significance.

Main body of abstract: Current targeting conventional markers (C-reactive protein, white blood cell, tumour necrosis factor-α, interleukins, etc.) are non-specific for diagnosing sepsis. Procalcitonin (PCT), a member of the calcitonin super family could be a critical tool for the diagnosis of sepsis. But to distinguish between bacterial versus viral infections, procalcitonin alone may not be effective. Rapid elevation in the concentration of procalcitonin and other newly emerging biomarkers during an infection and its correlation with severity of illness makes it an ideal biomarker for bacterial infection. Beside this, the procalcitonin levels can be used for monitoring response to antimicrobial therapy, diagnosis of secondary inflammations, diagnosis of renal involvement in paediatric urinary tract infection, etc. The present article summarizes the relevance of procalcitonin in the diagnosis of sepsis and how it can be useful in determining the therapeutic approaches.

Conclusion: Further studies are needed to better understand the application of PCT in the diagnosis of sepsis, differentiating between microbial and non-microbial infection cases and determining the therapeutic approaches for sepsis.

Keywords: Procalcitonin, Sepsis, Antibiotic therapy, Diagnostic marker

Background

During the course of evolution, our immune system has eventually developed to deal with infectious pathogen invasions by various host defence mechanisms. Inflammatory response is one of the primary responses to a microbial invasion, [1] which leads to the systemic illness which is referred to as sepsis. Its severity correlates with mortality [2–5]. It may occur as a result of infections acquired from community, hospitals or other healthcare facilities. There is an alarming number of 18 million new sepsis cases reported each year worldwide with mortality rate ranging from 30–50% [6]. Intensive care case pattern study reported frequent prevalence of sepsis in India, with 28.3% of patients contact sepsis during ICU stay and have 34% mortality rate [7].

All types of microbes like bacteria, virus, fungi and parasites can cause sepsis, but bacteria cause the most common pathogenic invasion [8–10]. During sepsis, the microorganisms invade to the blood stream and directly proliferate locally and release various virulent factors into the bloodstream [11]. These products can stimulate the release of endogenous mediators of sepsis from endothelial cells, monocytes, macrophages neutrophils and plasma cell precursors [12]. Sepsis-related inflammatory response arise when the body attempts to neutralize pathogenic infection which in turn leads to the activation of various mechanism with the immune cells to secrete inflammatory protein which in turn damage tissues and organs of the host [13, 14]. Clinical symptoms of sepsis include tachycardia, tachypnea, fever, leucocytosis, etc. Usually severe sepsis is accompanied with hypoperfusion or dysfunction of at least one organ. Sepsis associated with multiple organ dysfunction syndrome (MODS) or hypotension is known as septic shock [15].

* Correspondence: manojg@lifecarehl.com
Diagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekaryam (P.O), Trivandrum, Kerala, India

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Early diagnosis and prompt antimicrobial therapy is crucial in the treatment of sepsis for saving lives. Sepsis is a systemic inflammatory response syndrome (SIRS) that affect all organs. Hence, host responses including cytokine, cell markers, receptor biomarkers, coagulopathies, vascular endothelial damage, vasodilation, organ failure and scientific advancement in the field of molecular biology can equip us to screen wide range of protein markers in acute phase of sepsis development that helps in identifying relevant biomarkers to diagnose sepsis [16]. WBC, C-reactive protein (CRP) and interleukin-1 (IL-1) are the conventional markers used for diagnosis of sepsis. Compared to CRP, PCT has better diagnostic and prognostic value and will clearly distinguish viral of sepsis. Compared to CRP, PCT has better diagnostic and scientific advancement in the field of molecular biology can equip us to screen wide range of protein markers in acute phase of sepsis development that helps in identifying relevant biomarkers to diagnose sepsis [16].

Procalcitonin as diagnostic tool
An ideal biomarker should possess high diagnostic accuracy, for an early and rapid diagnosis. PCT is a recently re-discovered biomarker that fulfils many of these requirements especially in comparison to conventional and widely used other biomarkers that have demonstrated superior diagnostic accuracy for a variety of infections, including sepsis. PCT is helpful for early detection of sepsis as well as to monitor the antimicrobial treatment regimen. In fact, PCT can be a useful tool for antimicrobial stewardship and its utilization may safely lead to significant reduction of unnecessary administration of antimicrobial therapy. Laboratories and clinicians must comprehend the precincts of the present microbiological methods and the need for highly sensitive biomarker assays to facilitate accurate diagnosis and goal directed therapy in patients suspected of sepsis.

During sepsis conditions, microbes and their antigens stimulate numerous anti-inflammatory mediators, which will trigger the host immune response. Precursors, mature forms and degradation products of these mediators penetrate from the site of action into the circulation, where which can be measured theoretically. These
substances can be measured as surrogate markers for the diagnosis and the severity of infection. Exalted production of PCT during bacterial and its association with sepsis was first demonstrated by Asscot et al. [26]. The actual mechanism of production of PCT during infection is not known, but it assumes that bacterial lipopolysaccharides and sepsis released cytokines modulate the liver and peripheral blood mononuclear cells to produce PCT. Microbial infection induces the elevated expression of CALC 1 gene followed by the release of PCT product which is correlated with severity of disease and mortality.

The PCT as a biomarker proved successfully its clinical usefulness in determining the presence of sepsis. Moreover, it has been shown to correlate the extent and the severity of microbial invasion. It clearly showed the significance of early diagnosis of bacterial infected sepsis. PCT can be used for early detection of sepsis and prediction of outcome after major trauma. Muller et al. conducted a study in patients with community-acquired pneumonia; the serum PCT concentration could differentiate bacterial from viral causes. Out of 545 patients with pneumonia symptoms consulting at the emergency department (ED), 373 were suspected with true bacterial pneumonia; the area under the receiver operating characteristics (AUROC) curve for the PCT to predict bacterial pneumonia of 0.88. CRP was slightly less efficient (AUROC = 0.76) than PCT. PCT 0.1 ng/ml predicted bacterial pneumonia with 90% sensitivity and 59% specificity, whereas PCT 1 ng/ml showing 43% sensitivity and 96% specificity [27]. Several meta-analysis data suggest of heterogeneity for the PCT testing; however, elevated PCT concentrations strongly associated with all-cause mortality in sepsis patients [28].

Muller and colleagues conducted a study in consecutive critically ill patients to compare the usefulness of serum concentration of calcitonin precursor, CRP, IL-6 and lactate for the diagnosis of sepsis. Blood samples were collected at variable intervals during the course of disease (systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis and septic shock. Serum concentration of calcitonin precursor, CRP, IL-6 and lactate were elevated according to the severity of illness. Based on receiver operating characteristic (ROC) curve analysis, they concluded that PCT is the most reliable marker for the diagnosis of sepsis, with 89% of sensitivity and 94% of specificity [29]. Ibrahim et al. evaluated the utility of PCT as a routine biochemical tool compared to the traditional inflammatory marker CRP. They simultaneously measured PCT and CRP in 73 medico surgical ICU patients; according to the American College of Chest Physician (ACCP) criteria-based study group, 75% cases revealed SIRS in clinical representation. They observed 75% of diagnostic accuracy, 72% of specificity and sensitivity of 76% for PCT and concluded that PCT is superior to CRP in terms of accuracy in identification and assessment of severity of sepsis [30].

Study of Young et al. [31] evaluated the ability of PCT as an early detector of septic shock in patients with acute pyelonephritis secondary to ureteral calculi. They considered 49 patients and divided them into 2 groups: with and without septic shock. Platelet count, PCT, CRP, creatinine, erythrocyte sedimentation rate (ESR), albumin and white blood cells (WBC) were measured at the
time of admission to the emergency department before administrating antibiotic treatment. Univariate analysis shows higher PCT and CRP level and higher positive blood culture rate during septic shock. The multivariate model reveals that lower platelet count and higher PCT level are independent risk factors of septic shock. In ROC curve, the AUC (area under curve) was wider for PCT (0.929) compared to platelet count (0.822). At the cut-off of 0.52 ng/mL, PCT shows high sensitivity (86.7%) and specificity (85.3%). The study demonstrated that elevated PCT is an early independent predictor of development of septic shock in patients with sepsis induced by acute pyelonephritis associate with ureteral calculi.

**Comparison of procalcitonin and presepsin/sCD-14**

In 2004, presepsin was identified as a diagnosis marker and evaluated for sepsis. It became an alternative biomarker to aid the diagnosis of sepsis [32]. Recent studies shows that soluble cluster of differentiation 14 (sCD14) plays a significant role as biomarker with respect to diagnosis of sepsis. CD14 is a surface marker constituent of glycoprotein on monocytes and macrophages (mCD14) and serves as a high-affinity receptor towards lipopolysaccharides (LPSs), which is an essential building block of outer cell wall of gram-negative bacteria, and LPS-binding proteins (LPBs). CD14 binding to toll-like receptor 4 (TLR4) lead to activation of pro-inflammatory signalling cascade in bacterial infection [33, 34].

Along with PCT, other biomarkers alone or in combination are used in the diagnosis of sepsis, including presepsin, C-reactive protein (CRP), interleukin (IL), etc. However, the clinical value of these biomarkers independently or in combination is still at investigative stages [35]. Presepsin exists in the blood and urine of humans and comprises 99% of the total amount of CD14 in the human body, with a normal concentration of 2–6 μg/ml in serum [36]. When this was compared to PCT, presepsin also showed a similar diagnostic accuracy for sepsis with respect to area under curve (AUC) (Table 1) [37–40]. Accuracy of presepsin was similar to that of PCT, although presepsin had some superiority in the management of patients but Food and Drug Administration (FDA) approved PCT as a more reliable marker for sepsis. PCT level above 2.0 ng/ml on the first day of ICU admission could be associated with a higher risk for progression to severe sepsis and/or septic shock than PCT levels below 0.5 ng/mL. This diagnostic approach is also recommended in various guidelines [41].

**Procalcitonin as a tool for antibiotic therapy**

The introduction of antibiotics was in mid-20th century. Misuse and overuse of antibiotics launch the next misery known as antibiotic resistance by pathogens. Judicious use of antibiotics is of vital importance in clinical therapy [42]. Scott Fridin et al. analysed the Centres for Disease Control and Prevention (CDC) which conducted Emerging Infections Program (EIP), and thus a national administrative database (Marketscn Hospital Drug Database) was prepared to assess the potential for improvement of inpatient antibiotic prescribing. According to their study, reduction of incorrect antibiotic prescription can improve the use and patient safety [43].

Implementation of antibiotic stewardship helps to control unnecessary antibiotic prescribing as well as ensure the efficiency of treatment [44]. Inappropriate usage of medicines may lead to the development of antibiotic resistance in patients [45]. It is obligatory to reduce ‘blind’ prescription of drugs to avoid the evolution of secondary infection to antibiotics and obstruct the occurrence of drug resistance. An ideal marker should assist early diagnosis and capabilities to track the disease and facilitate the therapeutic interventions and decisions. The PCT is a better choice, compared to other markers which satisfy these features. An algorithm based on serial measurement of PCT can reduce the antibiotic exposure in septic patients [46]. According to the level of serum PCT, therapeutic decisions in patients were taken (Fig. 2). Based on reports, in transplant recipients, to minimize delays in the diagnosis of sepsis, it is paramount to recognize the specific risk factors for infection associated with each allograft type. Hence, PCT can be a better biomarker in detecting bacterial sepsis at initial stages. But the major limitations are to identify the causative bacteria. In addition, the particular surgical techniques involved in each type of transplantation may be closely related to the clinical manifestations of the infection process. Hence, further culturing and gram staining is required to identify the type of bacteria for further accurate treatments.

### Table 1 Comparison of diagnostic potential of procalcitonin and presepsin

| Reports                        | No. of subject | Area under curve (AUC) for the diagnosis of sepsis |
|-------------------------------|----------------|-----------------------------------------------|
|                               |                | Procalcitonin | Presepsine |
| Dunja Mihajlovic et al. (2017) | 100            | 0.750         | 0.730      |
| Christian Leli et al. (2016)   | 0.92           | 0.876         | 0.788      |
| Kada Klouche et al. (2016)     | 144            | 0.800         | 0.750      |
| Enguix-Armada A et al. (2016)  | 388            | 0.989         | 0.948      |
A study conducted in acutely febrile patients reveals that measurement of PCT is helpful in differentiating bacteria and non-bacterimic infectious episodes in patients. Based on the above observations, serum PCT level measurement is recommended for the guidance of antibiotic therapy [47]. Stolz D et al. evaluated the efficacy and safety of PCT guidance compared to standard therapy with antibiotic prescriptions in patients experiencing exacerbations of chronic obstructive pulmonary disease (COPD) [48]. Compared to standard therapy, PCT guidance reduce the antibiotic exposure (relative risk (RR), 0.56; 95% confidence interval (CI), 0.43 to 0.73; \( p < 0.0001 \)) and antibiotic prescription (40 vs. 72%, respectively; \( p < 0.0001 \)).

Schroeder et al. conducted a study in surgical intensive care patients with severe sepsis in which two classes were considered, PCT guided and control. For all patients, drug administration was based on microbiological spectrum. When the clinical signs of infection improved and PCT level decreased to <35% of the initial value, the antibiotic treatment was discontinued in PCT-guided patients. In control group, treatment was based on empirical rules. They observed that PCT-based algorithm reduces the use of antibiotic as well as the expense of treatment [49]. Lavrentieva et al. reported that PCT-guided algorithm for antibiotic therapy may contribute to the reduction of antibiotic exposure in burn intensive care unit. They enrolled 46 burn ICU patients for the study, wherein 24 patients received the therapy based on PCT guidance, which resulted in a smaller antibiotic exposure (10.1 ± 4 vs. 15.3 ± 8 days) without any negative impact on clinical outcome [50].

Kip and colleagues assessed the cost effectiveness of PCT-based algorithm. It was found to reduce the length of hospital stay, number of blood cultures and the duration of antibiotic therapy [51]. Antibiotic treatment based on PCT monitoring is a sensitive way of antibiotic usage in ICU patient with severe sepsis and septic shock [52]. Anna Prkno and co-workers reviewed various studies regarding the clinical trials and compared PCT-guided antibiotic stewardship with standard care and hospital mortality, duration of antimicrobial therapy and length of stay in the ICU. It was noticed that PCT guidance could not make better change in the mortality rate, but there was definitely a noteworthy effect on the duration of antimicrobial treatment [53, 54].

**Future of PCT for the management of sepsis**

Various studies are published revealing the wide application of PCT in medical field. Before selecting PCT as a biomarker, its limitations have to be studied. Further studies should be conducted to disclose even more application of PCT. The assay used for the detection must distinguish PCT levels between healthy individuals, non-
bacteremia patients and progressing SIRS. More sensitive assays should be developed to take forward the studies to the clinical level [55, 56].

Conclusion
The PCT is a unique biomarker having wide range of application in the medical field, compared to other conventional markers for sepsis. However, to diagnose invasive bacterial infection and their severity assessment of PCT levels alone may not be enough. Because of the possible complication in diagnosis of sepsis and the challenge in differentiating between microbial and non-microbial infection cases, it is unlikely that a single biomarker serve as an effective diagnosis tool. A combination of biomarkers may be more functional in the case of clinical application, but this may require further investigation in various aspects as a reliable diagnostic tool [57, 58]. Measurement of combinational biomarkers may require reliable and cost effective technology development. Selection of biomarkers plays a crucial role in technology development; consequently, assessment of combination of biomarkers like procalcitonin, sCD14-ST and other new biomarkers can be made use in evaluation of sepsis in all age groups. Combination of emerging new biomarkers with PCT could be used in terms of good clinical judgement based on which antimicrobial therapy may suggested, thus reducing the prescription and duration of antibiotic treatment. Combinational biomarker with PCT-guided antibiotic stewardship could be properly fabricated to develop a safer and affordable strategy for diagnosis of sepsis and its prognosis.

Acknowledgements
The authors would like to thank the management team of HLL for the extended support and guidance. The authors are thankful to Dr. Rajmohan G (Scientist E3) for the valuable comments during scripting of this article. We are also thankful to Ms. Jeslin Varghese (Senior Project Fellow) for the technical support in completing the study.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Authors’ contributions
AV, VM, SR, SK, LS, KR and MG participated in drafting and revising the manuscript. All authors have read and approved the final manuscript.

Authors’ information
Ms. Ashitha Vijayan, M. Sc Microbiology, working as Research Intern in Diagnostic Products lab of CRDC, HLL and involved in diagnostic kit developments.
Ms. Vanu Maya, M. Sc Biochemistry, working as Junior Project Fellow in Diagnostic Products lab of CRDC, HLL and involved in diagnostic kit developments.
Ms. Shilpa Ravindran, M. Sc Biochemistry, Working as Senior Project Fellow in Diagnostic Products lab of CRDC, HLL and involved in diagnostic kit developments.
Mr. Sairam R, M. Sc Biotechnology, working as Junior Scientist in Diagnostic Products lab of CRDC, HLL and involved in drug developments.
Dr. Lakshmi S, Ph.D Biotechnology, working as Senior Scientist in Diagnostic Products lab of CRDC, HLL and involved in drug developments.

Dr. Kartik Ramaswami, Ph.D Biotechnology, working as Junior Scientist in Diagnostic Products lab of CRDC, HLL and involved in clinical research.
Dr. Manoj G, Ph. D Biotechnology, working as Scientist E2 in Diagnostic Products lab of CRDC, HLL and involved in diagnostic kit developments.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 May 2017 Accepted: 21 July 2017
Published online: 03 August 2017

References
1. Markus B, Peter AW. The inflammatory response in sepsis. Trends Immunol. 2013;34(3):129–36.
2. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. Br Med J. 2007;335:879–83.
3. Dunja M, Snezana B, Arsen U, Biljana D, Vladimir V. Use of procalcitonin and procalcitonin for prediction of SeptiFast results in critically ill patients. J Crit Care. 2017;40:197–201.
4. Angus DC, Van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
5. Moore LJ, McKinley BA, Turner K. The epidemiology of sepsis in general surgery patients. J Trauma. 2011;70(6):72–80.
6. Slade E, Tamber PS, Vincent JL. The surviving sepsis campaign, raising awareness to reduce mortality. Crit Care. 2003;7(1):1–2.
7. Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, Govil D, Chowla R, Kulkarni AP, Samavedan S, Jani CK, Rungta N, Samaddar DP, Mehta S, Venkataraman R, Hegde A, Bande BD, Dhanuka S, Singh V, Tewari R, Zippe K, Sathe P. INCIDAPS Study Investigators. Intensive care in India: the Indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20(4):216–25.
8. Feldmann H, Geistert WB. Ebola, hemorrhagic, fever. Lancet. 2011;377(9768):849–62.
9. Calk JA, Alleva LM, Mills AC, Cowden WB. Pathogen of malaria and clinically similar conditions. Clin Microbio Rev. 2004;17(3):509–39.
10. Paesler S, Walker DH. Pathogenesis of the viral hemorrhagic fever. Annu Rev Pathol. 2013;8:411–40.
11. Livorsi DJ, Stenfyn J, Stephens DS. Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitidis. Contrib Microbiol. 2011;17:31–47.
12. Willey J, Sherwood L, Christopher JW. Prescotts’ Microbiology, International edition. 8th ed; 2011. p. 97.
13. Rimmelé T, Leli C, Payen D, Cantaluppi V, Marshall J, Gomez H, Gomez A, Murray P, Kellum JA. Immune cell phenotype and function in sepsis. Shock. 2016;45(3):282–91.
14. Chen X-h, Yin Y-j, Zhang J-x. Sepsis and immune response. World J Emerg Med. 2011;2(2):88–92.
15. Reinhart K, Bauer M, Reedeman NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. J Clin Microbiol. 2010;48:609–34.
16. Sakr Y, Brgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med. 2008;36:2014–22.
17. Usama M, Nemrin A, Ayman A, Sultan MH. Serum procalcitonin in viral and bacterial meningitis. J Glob Infect Dis. 2011;3:14–8.
18. Hira C, Juhua Z, Yin Z, Mir MA, Franklin M, Prakash SN, Mtzi N. Role of Cytokines as a Double-edged Sword in Sepsis. In Vivo. 2013;27(6):669–84.
19. Angus DC, Linde-Zwible WT, Liddicker J, Clermont G, Carillo J, Pinsky MR. Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome and associated cost of care. Crit Care Med. 2001;29:1303–10.
20. Standage SW, Wong HR. Biomarkers for paediatric sepsis and septic shock. Expert Rev Anti-Infect Ther. 2011;9(1):71–9.
21. Moya F, Nieto A, Jose LR. Calcitonin biosynthesis: evidence for a precursor. Eur J Biochem. 1975;55:407–13.

22. Allison J, Hall L, Machtynger L, Craig RK. The construction and partial characterisation of plasmid containing complementary DNA sequences to human calcitonin precursor polyprotein. Biochem J. 1981;199:725–31.

23. Jacobs JW, Lund PK, Potts JT, Bell NH, Habener JF. Procalcitonin is a glycoprotein. J Biol Chem. 1981;256(28):2803–7.

24. Katherine S, Roma LH. Procalcitonin: an emerging biomarker of bacterial sepsis. Clin Microbiol Newsletter. 2001;3:171–8.

25. Müller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396–404.

26. Assicot M, Gendrel D, Cazin H, Raymond J, Guilbaud J, Bohouo C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:514–5.

27. Müller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Huber P, Müller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.

28. Dan I, Longswi S, Gengchong H, Peng Y, Livin X. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0129450.

29. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977–83.

30. Nargis W, Ibrahim MD, Ahamed BU. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient. Int J Crit Illn Inj Sci. 2014;4:195–9.

31. Young HK, Yoon SJ, Sin-Youl P, Kim SJ, Song PH. Procalcitonin determined in septic shock in patient with sepsis associated with ureteral calculi. Int Braz J Urol. 2016;42(2):270–4.

32. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Inai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.

33. Romualdo LG, Torrella PE, González MV, Sánchez RJ, Holgado AH, Freire AO. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the emergency department. Clin Biochem. 2014;47:505–8.

34. Camussi G, Miano F, Biancone L, De Martino A, Bussolati B, Montrucchio G, et al. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol. 1995;155:316–24.

35. Jayawan W, Liren H, Gachua Z, Fenping W, Taiping H. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0133057.

36. Wacker C, Prikos A, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care. 2013;17:R291.

37. Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003;36:823–4.

38. Pradeppe M, Xu J, Karen DHM. Biomarkers for neonatal sepsis: recent developments. Dovepress. 2014;4:157–68.

39. Taylor R, Jones A, Kelly S, Simpson M, Mabey J. A review of the value of procalcitonin as a marker of infection. Cureus. 2017;9(4):e1148.

40. Caker Madenci O, Yakupoglu S, Benzonana N, Yucel N, Akbaba D, Orçan KA. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2013;39:664–9.

41. Elia P, Marco U, Claudia G, Manuela L, Tilde M, Enrico L, Giulio M, Stefania B. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med. 2014;52(10):1395–400.

42. Kimberly YH, Jernigan J, Shehab N, Herrera R, LC MD, Schneider A, Arjun S. Vital signs: improving antibiotic use among hospitalized patients. Mob Mort Wky Rep. 2014;63(10):194–200.

43. Liew YX, Chibbeck MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). Eur J Clin Microbiol Infect Dis. 2011;30:853–5.

44. Larson E. Community factors in the development of antibiotic resistance. Annu Rev Public Health. 2007;28:435–47.

45. Simon P, Millbrandt EB, Emlett LL. PCT-guided antibiotics in severe sepsis. Crit Care. 2008;12:309.

46. Chirouze C, Schuhmacher H, Rabaud C, Gil H, Khayat N, Estavoyer JM, May T, Hoen B. Low-serum procalcitonin level accuracy predicts the absence of bacteriaemia in adult patients with acute fever. Clin Infect Dis. 2002;35:156–61.

47. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.

48. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009;394(2):221–6.

49. Lavrentieva A, Kontou P, Soulbunioti V, Kiournti J, Chrysoy O, Bitzani M. Implementation of a procalcitonin-guided algorithm for antibiotic therapy in the burn intensive care unit. Ann Burns Fire Disasters. 2015;28(3):163–70.

50. Kp MM, Kusters R, Uzman J, Steuten MA. PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015;18(11):944–53.

51. Nobre V, Harbarth S, Graf JD, Rohner P, Jerome S. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Resp Crit Care Med. 2008;177:498–505.

52. Prikos A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care. 2013;17:R291.

53. Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis. 2003;36:823–4.

54. Pradeppe M, Xu J, Karen DHM. Biomarkers for neonatal sepsis: recent developments. Dovepress. 2014;4:157–68.

55. Taylor R, Jones A, Kelly S, Simpson M, Mabey J. A review of the value of procalcitonin as a marker of infection. Cureus. 2017;9(4):e1148.

56. Caker Madenci O, Yakupoglu S, Benzonana N, Yucel N, Akbaba D, Orçan KA. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2013;39:664–9.